Hodgkin Lymphoma

Back

Practice Essentials

Hodgkin lymphoma is a potentially curable lymphoma. The World Health Organization classifies Hodgkin lymphoma into the following types[1, 2] :



View Image

Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin an....

Signs and symptoms

Features of Hodgkin lymphoma include the following:

See Presentation for more detail.

Diagnosis

Laboratory tests include the following:

Imaging studies include the following:

A histologic diagnosis of Hodgkin lymphoma is always required. An excisional lymph node biopsy is recommended because the lymph node architecture is important for histologic classification.

When a patient presents with neck lymphadenopathy and risk factors for a head and neck cancer, a fine-needle aspiration is usually advised as the initial diagnostic step, followed by excisional biopsy if squamous cell histology is excluded.

Bone marrow biopsies are indicated in some cases. Bone marrow involvement is more common in elderly patients and those with advanced-stage disease, systemic symptoms, or a high-risk histology.

Central nervous system evaluation by lumbar puncture and magnetic resonance imaging should be performed if symptoms or signs of CNS involvement are present.

The Ann Arbor classification is used most often for Hodgkin lymphoma, as follows:

See also the Medscape article Hodgkin Lymphoma Staging.

See Workup for more detail.

Management

General treatment principles include the following:

See also the Medscape article Hodgkin Lymphoma Treatment Protocols.

Published guidelines from the National Comprehensive Cancer Network (NCCN),[4] the European Society for Medical Oncology (ESMO),[5] and the International Harmonization Project[6] provide consensus opinions from leading experts on evidence-based approaches to the diagnosis and treatment of Hodgkin lymphoma. See Guidelines.

The radiation fields used in the treatment of Hodgkin lymphoma are generally defined as follows:

The following induction regimens are given as initial treatment for Hodgkin lymphoma:

Brentuximab vedotin plus AVD is indicated as first-line therapy for previously untreated stage III-IV classical Hodgkin lymphoma.

When induction chemotherapy fails, or patients experience relapse, salvage chemotherapy is generally given. Salvage regimens incorporate drugs that are complementary to those that failed during induction therapy. Commonly used salvage regimens include the following:

High-dose chemotherapy at doses that ablate the bone marrow is feasible with reinfusion of the patient's previously collected hematopoietic stem cells or infusion of stem cells from a donor source. Historically, hematopoietic stem cells have been obtained from bone marrow, but they are now typically obtained by pheresis of peripheral blood lymphocytes. A validated and relatively safe conditioning regimen for autologous transplantation is the BEAM regimen (carmustine [BCNU], etoposide, cytarabine, melphalan).[7]

Toxicities associated with treatment regimens include the following:

See Treatment and Medication for more detail.

Background

Hodgkin lymphoma (formerly, Hodgkin disease) is a potentially curable lymphoma with distinct histology, biologic behavior, and clinical characteristics. The disease is defined in terms of its microscopic appearance (histology) (see the image below) and the expression of cell surface markers (immunophenotype). (See Pathophysiology.)



View Image

Micrograph of Hodgkin lymphoma in a fine-needle aspiration lymph node specimen (field stain). Eosinophils, Reed-Sternberg cells, plasma cells, and his....

To diagnose Hodgkin lymphoma a histologic evaluation is always required, and an excisional lymph node biopsy is recommended for this purpose (see Workup). Various imaging studies are used to stage the patient.

Treatment for Hodgkin lymphoma is with multiagent chemotherapy, with or without radiation therapy. Treatment seeks to balance the risk of treatment failure with the risk of treatment side effects (see Treatment).

See also the Medscape article Pediatric Hodgkin Disease.

Pathophysiology

The World Health Organization (WHO) classifies Hodgkin lymphoma into five types.[1] Nodular sclerosing, mixed cellularity, lymphocyte depleted, and lymphocyte rich are the four types referred to as classical Hodgkin lymphoma. The fifth type, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), is a distinct entity with unique clinical features and a different treatment paradigm.

In classical Hodgkin lymphoma, the neoplastic cell is the Reed-Sternberg cell (see the image below).[8, 9] Reed-Sternberg cells comprise only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils, and histiocytes.



View Image

A Reed-Sternberg cell in Hodgkin lymphoma. Reed-Sternberg cells are large, abnormal lymphocytes that may contain more than one nucleus. Image courtesy....

Most Reed-Sternberg cells are of B-cell origin, derived from lymph node germinal centers but no longer able to produce antibodies. Hodgkin lymphoma cases in which the Reed-Sternberg cell is of T-cell origin are rare, accounting for 1-2% of classical Hodgkin lymphoma.

The Reed-Sternberg cells consistently express the CD30 (Ki-1) and CD15 (Leu-M1) antigens. CD30 is a marker of lymphocyte activation that is expressed by reactive and malignant lymphoid cells and was originally identified as a cell surface antigen on Reed-Sternberg cells. CD15 is a marker of late granulocytes, monocytes, and activated T-cells that is not normally expressed by cells of B lineage.

Classical Hodgkin lymphoma

Classical Hodgkin lymphoma is classified into the following 4 types:

Nodular sclerosing Hodgkin lymphoma

In NSHL, which constitutes 60-80% of all cases of Hodgkin lymphoma, the morphology shows a nodular pattern. Broad bands of fibrosis divide the node into nodules. The capsule is thickened. The characteristic cell is the lacunar-type Reed-Sternberg cell, which has a monolobated or multilobated nucleus, a small nucleolus, and abundant pale cytoplasm.

NSHL is frequently observed in adolescents and young adults. It usually involves the mediastinum (see the image below) and other supradiaphragmatic sites.



View Image

Nodular sclerosing Hodgkin lymphoma of the mediastinum. The diagnosis is strongly suggested by the presence of distinct nodules on the cut surface of ....

Mixed-cellularity Hodgkin lymphoma

In MCHL, which constitutes 15-30% of cases, the infiltrate is usually diffuse. Reed-Sternberg cells are of the classical type (large, with bilobate, double or multiple nuclei, and a large, eosinophilic nucleolus). MCHL commonly affects the abdominal lymph nodes and spleen. Patients with this histology typically have advanced-stage disease with systemic symptoms. MCHL is the histologic type most commonly observed in patients with human immunodeficiency virus (HIV) infection.

Lymphocyte-depleted Hodgkin lymphoma

LDHL constitutes less than 1% of cases. The infiltrate in LDHL is diffuse and often appears hypocellular. Large numbers of Reed-Sternberg cells and bizarre sarcomatous variants are present.

LDHL is associated with older age and HIV-positive status. Patients usually present with advanced-stage disease. Epstein-Barr virus (EBV) proteins are expressed in many of these tumors. Many cases of LDHL diagnosed in the past were actually non-Hodgkin lymphomas, often of the anaplastic large-cell type.

Lymphocyte-rich classical Hodgkin lymphoma

LRHL constitutes 5% of cases. In LRHL, Reed-Sternberg cells of the classical or lacunar type are observed, with a background infiltrate of lymphocytes. It requires immunohistochemical diagnosis. Some cases may have a nodular pattern. Clinically, the presentation and survival patterns are similar to those for MCHL.

Nodular lymphocyte-predominant Hodgkin lymphoma

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) constitutes 5% of cases. It is a distinct clinical entity and is not considered part of the classical Hodgkin lymphoma type. Typical Reed-Sternberg cells are either infrequent or absent in NLPHL. Instead, lymphocytic and histiocytic (L&H) cells, or "popcorn cells" (their nuclei resemble an exploded kernel of corn), are seen within a background of inflammatory cells, which are predominantly benign lymphocytes (see the image below). Unlike Reed-Sternberg cells, L&H cells are positive for B-cell antigens, such as CD20, and are negative for CD15 and CD30.



View Image

Very high magnification micrograph of nodular lymphoctye predominant Hodgkin lymphoma (NLPHL), with a popcorn-shaped Reed-Sternberg cell (hematoxylin ....

A diagnosis of NLPHL needs to be supported by immunohistochemical studies, because it can appear similar to LRHL or even some non-Hodgkin lymphomas.

Etiology

The etiology of Hodgkin lymphoma is unknown. Infectious agents, particularly Epstein-Barr virus (EBV), may be involved in the pathogenesis.[10, 11] Depending on the study, data show that up to 30% of cases of classical Hodgkin lymphoma may be positive for EBV proteins.[12] In addition, a case control study supports an increased risk of classical Hodgkin lymphoma after EBV infection, with a risk of approximately 1 in 1000 cases.[13]

The incidence of EBV positivity varies with subtype. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) rarely expresses EBV proteins,[14] whereas in classical Hodgkin lymphoma, EBV positivity is most common in the mixed-cellularity variant.[15] However, the exact mechanism by which EBV can lead to Hodgkin lymphoma is not known.

HIV-positive patients also have a higher incidence of Hodgkin lymphoma compared with HIV-negative patients. However, Hodgkin lymphoma is not considered an AIDS-defining neoplasm.

Genetic predisposition plays a role in the pathogenesis of Hodgkin lymphoma. Approximately 1% of patients with Hodgkin lymphoma have a family history of the disease, and siblings of an affected individual have a 3- to 7-fold increased risk of developing the disease.[16] Most evidence for a genetic etiology has been established in the distinct subtype of nonsclerosing Hodgkin lymphoma (NSHL). NSHL has been shown to be one of the most heritable types of neoplasm, with a 100-fold increased risk in identical twins.[17, 18]

There is evidence that NSHL may result from an atypical immune response to a virus or other trigger, in an individual with a genetic predisposition to such a response.[19] For decades, specific human leukocyte antigen (HLA) class II genotypes, including HLA-DRB1 and HLA-DQB1, have been known to be associated with NSHL, and this has been confirmed by genome-wide association studies.[20] Several single-nucleotide polymorphisms in the 6p21.32 region, which is rich in genes associated with immune function, have also been associated with NSHL risk.[21]

Epidemiology

United States statistics

Information regarding the incidence and mortality of Hodgkin lymphoma in the United States can be found at the National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) database Website. The NCI reports that rates of new Hodgkin lymphoma cases have been falling on average 1.2% each year over the last 10 years. As of 2010-2014, the age-adjusted incidence is 2.6 cases per 100,000 population. Death rates have decreased slowly but steadily in recent decades, but were stable at 0.3 per 100,000 population over 2012-2014.[22]

Data are also collected by the American Cancer Society (ACS). The ACS estimates that 8500 new cases of Hodgkin lymphoma will be diagnosed in 2018, and 1050 deaths will occur.[23]

International statistics

In Europe and other developed countries, the incidence parallels US data.[24, 25] United Kingdom data from 2015 show a crude incidence rate of 3.3 cases per 100,000 population (3.8 cases per 100,000 males and 2.8 cases per 100,000 females). Since the early 1990s, incidence rates of Hodgkin lymphoma in the UK have risen 35%.[26]

Race-, sex-, and age-related differences in incidence

Hodgkin lymphoma incidence rates in the United States vary by race and sex. In general, incidence is higher in males than in females. The sex predilection is most pronounced in children, with 85% of cases affecting boys.[22] The lowest incidence is found in Asians and Pacific Islanders.[22]

The incidence of Hodgkin lymphoma varies with age, with a clear bimodal distribution that is consistent across most countries and studies.[27] The initial peak is in young adults (15-34 years) and older adults (>55 years).[28] There is also a difference in subtype based on age, with young adults having nodular sclerosing Hodgkin lymphoma (NSHL) and older adults tending to have MCHL.

Prognosis

Patient prognosis is largely based on the stage of the disease and various prognostic factors, which may be defined differently across various major cooperative groups (eg, German Hodgkin's Study Group [GHSG] vs European Organisation for Research and Treatment of Cancer [EORTC] and others).[29] (See also Staging.)

The SEER data report an 86.2% overall 5-year survival rate from 2006-2012.[22] Table 1 summarizes the stage distribution and 5-year relative survival at diagnosis for the same period for all races and both sexes.[22] In addition to the stage of the disease, many factors contribute to the likelihood of survival from Hodgkin lymphoma (see Staging). Factors that influence prognosis include patient age, presence or absence of B symptoms, stage of disease, and elevation of erythrocyte sedimentation rate.[30]

Table 1. Stage Distribution and 5-Year Relative Survival by Stage at Diagnosis for All Races and Both Sexes: 2011-2015



View Table

See Table

The most commonly used prognostic system is the International Prognostic System (IPS), which uses the following variables to The most commonly used prognostic system is the International Prognostic System (IPS), which uses the following variables to determine prognosis[31] :

Each of the above variables is assigned 1 point. The total number of points for prognostic factors is used to determine risk. When applied to a group of 5141 patients with Hodgkin lymphoma the IPS produced the following groups of 5-year survival rates[31] :

These results have been validated in other populations as well, including in patients undergoing stem cell transplant.[32, 33] However this scoring system is most applicable to patients with advanced-stage disease (stages III and IV).

Patient Education

Before beginning treatment, patients with Hodgkin lymphoma should be counseled about the potential complications of therapy, including the risk of cardiac disease, lung toxicity, and secondary cancers. Patients should also be apprised of the potential loss of fertility that may arise from treatments such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) chemotherapy, escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy, and pelvic irradiation, so that they may explore fertility-preserving options such as sperm banking, oral contraceptive use, or oophoropexy. Although less likely, infertility can also occur with ABVD therapy (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine).

Female patients who have received chest radiation therapy should be encouraged to perform regular breast self-examinations. All patients should be counseled on health habits that may help reduce the risk of cancer and cardiovascular disease, including avoidance of smoking, control of lipids, and the use of sunscreen.

Although splenectomy is uncommon with modern therapy, any patient who has undergone this procedure needs to be counseled about vaccination needs and their long-term risk of infection.

Patients should understand the risk of psychosocial problems that may affect survivors of Hodgkin lymphoma. Consultations with social workers, psychologists, and psychiatrists may be helpful.

For patient education information, see the Cancer Center as well as Lymphoma.

History

Features of Hodgkin lymphoma include the following:

Physical Examination

Physical examination findings in Hodgkin lymphoma include the following:

Approach Considerations

The patient’s history and physical examination are important for diagnosis, but the foundation for determining the ideal Hodgkin lymphoma treatment is accurate staging. Imaging, sampling (biopsy), and an assessment of prognostic factors are required for staging. Hematologic (complete blood cell [CBC] count) and blood chemistry studies may reveal nonspecific findings in patients with Hodgkin lymphoma that may be associated with disease extent. Several of these findings have been used as prognostic factors.

Formerly, staging laparotomy and laparoscopy were the standard of care in Hodgkin lymphoma, but with modern imaging and treatment paradigms these procedures are no longer needed.

Laboratory Tests

Complete blood cell (CBC) count studies for anemia (low red blood cell [RBC] count), lymphopenia (low white blood cell [WBC] count), excess neutrophils (neutrophilia), or eosinophils (eosinophilia) should be performed. Some of these factors have prognostic implications, as noted under Prognosis. Hodgkin lymphoma–associated anemia is most commonly the anemia of chronic disease. However, it may result from bone marrow involvement by tumor or, rarely, from the presence of an autoantibody (as indicated by a positive warm-agglutinin on a Coombs test). Platelet counts may be increased or decreased.

The erythrocyte sedimentation rate (ESR)—a general marker of inflammation—may be elevated in Hodgkin lymphoma. An elevated ESR has been associated with worse prognosis. However, the ESR is a nonspecific test that should not be used for Hodgkin lymphoma screening.

Lactate dehydrogenase (LDH) may be increased. LDH levels may correlate with the bulk of disease.

Serum creatinine may be elevated in the rare cases of nephrotic syndrome associated with Hodgkin lymphoma. Levels of alkaline phosphatase (ALP) may be increased due to the presence of liver or bone involvement. Other uncommon laboratory findings include hypercalcemia, hypernatremia, and hypoglycemia (due to the presence of insulin autoantibodies).

A test for human immunodeficiency virus (HIV) is important in the workup of Hodgkin lymphoma, because antiretroviral therapies can improve disease outcomes in HIV-positive patients.[3] Screening for hepatitis B and C should also be considered.

Serum levels of cytokines (interleukin [IL]-6, IL-10) and soluble CD25 (IL-2 receptor) correlate with tumor burden, systemic symptoms, and prognosis, but these studies are generally obtained only in special situations or in the context of a clinical trial.

Imaging Studies

Imaging studies are important for accurate staging of Hodgkin lymphoma. These studies include plain x-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans. In addition, imaging studies can help to define disease bulk, which has prognostic implications. The definition of bulky disease varies, but in general is defined as any nodal mass greater than 10 cm (>5 cm in some studies) and a mediastinal mass greater than one third the thoracic diameter as measured at T5/6.

CT Scanning

Historically, posteroanterior (PA) and lateral chest x-rays have been used to measure mediastinal mass in relationship to thoracic diameter. This approach remains the gold standard, but with the availability of cross-sectional imaging in CT scanning, chest radiography has been largely replaced by CT. See the image below.



View Image

A computed tomography (CT) scan showing bulk disease in a patient with Hodgkin lymphoma.

On CT scans of the chest, abdomen, and pelvis, possible abnormal findings include enlarged lymph nodes, hepatomegaly and/or splenomegaly (with or without focal parenchymal abnormalities), lung nodules or infiltrates, and pleural effusions (see the image below).



View Image

This computed tomography scan is from a 46-year patient with Hodgkin lymphoma at the level of the neck. Enlarged lymph nodes are visible on the left s....

PET scanning

PET scanning is now considered essential to the initial staging of Hodgkin lymphoma, because of its ability to distinguish between viable tumor and necrosis or fibrosis in residual masses that are often present after treatment in patients who have no other clinical or biochemical evidence of disease.[36] This imaging study is often performed in conjunction with CT scanning (see the images below).[37] A mediastinal mass, representing mediastinal lymphadenopathy, is a very common finding in classical Hodgkin lymphoma, although it is uncommon in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).

The American College of Radiology does not recommend changing chemotherapy or omitting radiation therapy based on PET scan response for early-stage patients.[29, 30]



View Image

A positron emission tomography (PET) scan obtained with fluorodeoxyglucose (FDG) that shows increased FDG uptake in a mediastinal lymph node.



View Image

This image depicts a computed tomography (CT) scan, positron-emission tomography (PET) scan, and maximum intensity projection (MIP) PET scan from a pa....

Biopsy and Histologic Findings

A histologic diagnosis of Hodgkin lymphoma is always required. An excisional lymph node biopsy is recommended because the lymph node architecture is important for histologic classification (see the image below). When a patient presents with neck lymphadenopathy and risk factors for a head and neck cancer, a fine-needle aspiration is usually advised as the initial diagnostic step, followed by excisional biopsy if squamous cell histology is excluded.



View Image

Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin an....

Bone marrow biopsies are indicated in some cases. Bone marrow involvement is more common in elderly patients and those with advanced-stage disease, systemic symptoms, or a high-risk histology. However, given the low incidence of bone marrow involvement, some experts and expert groups feel that bone marrow biopsy can be omitted, particularly in early-stage disease. There is a bone marrow risk calculator available to help determine need for bone marrow biopsy.[38]

Sampling of a pleural effusion by thoracentesis and examination of the cells obtained may be useful in the evaluation of Hodgkin lymphoma. The pleural fluid may be an exudate or transudate, or it may be chylous.

Central nervous system (CNS) evaluation by lumbar puncture and magnetic resonance imaging (MRI) should be performed if symptoms or signs of CNS involvement are present. CNS involvement with Hodgkin lymphoma is exceedingly rare, but it has been reported.

Staging

Clinical staging involves assessment of disease extent by clinical examination, history, and imaging techniques. The Ann Arbor classification (1971) is used most often for Hodgkin lymphoma. It classifies cases into the following four stages, principally on the basis of lymph node involvement:

Involvement of the liver or the bone marrow is considered stage IV disease. For staging classifications, the spleen is considered to be a lymph node area. Involvement of the spleen is denoted with the S suffix (ie, IIBS).

A or B designations denote the absence or presence of B symptoms. A "B" designation includes the presence of one or more of the following:

An "A" designation is the absence of the above.

An "X" designation is sometimes used to indicate the presence of bulky disease (ie, bulk >10 cm).

Spread of Hodgkin lymphoma takes place via the lymphatics, hematogenous routes, and direct extension. Contiguous involvement of extranodal sites (eg, involvement of the lung parenchyma due to direct extension of large mediastinal lymphadenopathy) is not considered stage IV disease. Rather, it is designated with the E suffix (ie, IIBE).

Unfavorable factors in Hodgkin lymphoma are discussed under Prognosis.

See also the Medscape article Hodgkin Lymphoma Staging.

Approach Considerations

Treatment of Hodgkin lymphoma is tailored to disease type, disease stage, and an assessment of the risk of resistant disease. Hodgkin lymphoma is considered to be a curable malignancy, but therapies for this disease can have significant long-term toxicity. General treatment modalities include radiation therapy, induction chemotherapy, salvage chemotherapy, and hematopoietic stem cell transplantation.

The current treatment of Hodgkin lymphoma seeks to maximize the risk-benefit ratio of treatment. Thus, treatment focuses on tailoring therapy to each patient according to age, risk of short-term and long-term toxicity, and risk of relapse.

Classical Hodgkin lymphoma stages

In general, the management of Hodgkin lymphoma depends on the subtype. Most clinicians divide classical Hodgkin lymphoma into the following three general groups:

However, favorable disease is defined differently by different groups. The two most commonly used definitions are that of the European Organization for the Research and Treatment of Cancer (EORTC) and the German Hodgkin Study Group (GHSG).

The EORTC definition uses the following patient criteria[39] :

The GHSG definition uses the following criteria[40] :

With either definition, any patient with early-stage disease who does not meet the above criteria is considered to have early-stage unfavorable disease. In general, patients with early-stage favorable disease are treated with less intense chemotherapy and radiation regimens than those that are used for early-stage unfavorable disease.

Advanced-stage disease is generally treated with chemotherapy alone, with radiation therapy reserved for selected patients.

Treatment toxicity

Short-term toxicity varies based on the regimen and modalities used (chemotherapy, radiation, combination of both, and stem cell transplantation) and include:

Long-term toxicities vary based on patient age and treatment regimen. In general, the older the patient, the less the concern for long-term toxicity. Long-term toxicities and monitoring are described in detail later, but include the following:

Treatment goals

Given the curable nature of this disease and patients’ long-term survival, goals for treatment are the following:

The overarching theme is assessing patients individually for their extent of disease, disease-related prognosis, associated conditions, risk of relapse, and long-term survival. By taking these factors into account, treatment can be tailored to each patient.

There are several examples of changes to treatment over the last several decades that illustrate these goals, such as the following:

The above considerations apply mainly to classical Hodgkin lymphoma, but many of these principles can be applied to nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) as well. In general, NLPHL is clinically distinct from classical Hodgkin lymphoma in that NLPHL generally presents as early-stage disease that can be treated with local measures (surgery, radiation) or followed expectantly. However, some cases of NLPHL can transform to aggressive non-Hodgkin lymphomas that are treated using standard protocols. It is important to note the differences in immunophenotype; for example, NLPHL being CD20-positive allows for successful treatment with rituximab either alone or in combinations.

See also Hodgkin Lymphoma Treatment Protocols.

Clinical trials and consultations

Because of the limited number of patients with Hodgkin lymphoma and the importance of the clinical questions that remain about optimal disease management, patient involvement in clinical trials is strongly encouraged. It is also recommended that clinicians seek the following consultations in cases of Hodgkin lymphoma:

Goals of Therapy and Response Assessment

Hodgkin lymphoma has gone from an incurable disease to one with a cure rate of almost 75%.[41] In general, the goal of therapy is to obtain complete remission.

Treatment response criteria are defined as follows:

The primary goal of therapy is achievement of a CR, but even in patients who fail to do so, there are effective salvage regimens available that can result in long-term survival or cure.[42]

Patients are assessed for response in various ways. Prior to each cycle of therapy, the patient is evaluated by a clinician who performs a history and physical examination. In addition, laboratory studies are usually obtained. In general, a CT scan is performed midway through the planned treatment to assess for response (particularly if there are no peripheral lesions that are assessable by physical examination).

Mid-treatment PET or combined PET/CT scans are increasingly used to help guide therapy. The current literature supports the use of interim PET or PET/CT scanning to provide prognostic information at any stage and to adapt therapy in advanced Hodgkin lymphoma.[43, 44, 45]

Guidelines recommend obtaining PET scans at least 6-8 weeks after completion of therapy. Some expert societies recommend waiting 8-12 weeks[36] because of the high-rate of false-positive scans.[46] If a scan is obtained, any positive result should lead to performance of a biopsy to confirm residual disease prior to altering therapy.[47, 36]

Radiation Therapy

For treatment of classical Hodgkin lymphoma, radiation therapy is often administered in combination with chemotherapy. However, such treatment is dependent on the disease stage and bulk as well as where the patient is being treated. Although the role of radiation is becoming increasingly controversial in the treatment of Hodgkin lymphoma, it is still used in many patients.

The radiation fields used in the treatment of Hodgkin lymphoma have evolved to maximize response while minimizing toxicity. Although there are several definitions of radiation fields, the following are generally used:

ISRT is largely replacing IFRT. Current NCCN and international guidelines recommend ISRT for Hodgkin lymphoma.[4, 49]

In addition to the field used, the dose of radiation is also changing. The standard is typically 30-40 Gy (administered in single, daily fractions of 1.8-2 Gy, 5 times/wk), with the option of a boost of 6 Gy to sites of concern.[50, 51, 52]

Induction Chemotherapy Regimens

The following induction regimens are given as initial treatment for Hodgkin lymphoma:

All the medications in these regimens are given intravenously, except for prednisone and procarbazine, which are given orally.

The MOPP regimen was the first effective combination chemotherapy for Hodgkin lymphoma. This regimen is primarily of historical importance and is rarely used in current clinical practice, as it is less effective and more toxic than modern regimens.

The ABVD regimen is the standard of care for the treatment of classical Hodgkin lymphoma, particularly in the United States. ABVD is superior to MOPP in terms of disease-free survival (DFS) and has a lower incidence of sterility and secondary leukemia.[53]

The A+AVD regimen is a modification of the ABVD regimen, with brentuximab vedotin added and bleomycin omitted. It is the newest FDA-approved regimen for patients with stage III or IV classic Hodgkin lymphoma. Approval was based on a phase III trial that showed improved modified progression-free survival (PFS) compared with ABVD.[54] However, this trial has received criticism over its use of modified PFS as opposed to standard PFS, and long-term outcomes are awaited.

The Stanford V regimen is a multidrug regimen with irradiation included as part of standard therapy.[55] The drugs are administered weekly, alternating myelosuppressive and nonmyelosuppressive agents, for 12 weeks. Involved-field radiation (IFRT) at the conclusion of the 12-week treatment is an important part of this regimen. A potential advantage of the Stanford V regimen is that its use of a broad spectrum of chemotherapy drugs can limit the exposure (and potential side effects) of any single drug. However, several studies have failed to show superiority over ABVD, and the latter regimen remains the standard.[56]

The BEACOPP regimen was developed in Germany and is the default standard regimen there.[57] A dose-intensified version of BEACOPP (escalated BEACOPP), with higher doses of etoposide, doxorubicin, and cyclophosphamide and the addition of granulocyte colony-stimulating factor (G-CSF) for neutrophil support, has also been developed and may be useful for unfavorable, advanced-stage Hodgkin lymphoma. However, escalated BEACOPP is associated with greater hematologic toxicity and a higher incidence of secondary malignancies, including acute myelogenous leukemia (AML).

A study by Viviani et al demonstrated that BEACOPP produced better initial outcomes in patients with advanced Hodgkin lymphoma than treatment with ABVD but found no significant long-term differences between the regimens.[58] A meta-analysis by Bauer et al found that patients aged 16-60 years with early unfavorable or advanced stage disease benefited from escalated BEACOPP in terms of progression-free survival; however, no significant difference was noted in overall survival.[59]

More recently, a randomized comparison study by Mounier et al, in 150 low-risk patients with an International Prognostic Score (IPS) of 0-2, found that progression or relapses were more frequent with ABVD than BEACOPP (17 versus 5 patients, respectively).[60] In contrast, a randomized comparison study by Carde et al in 549 patients with high-risk stage III-IV Hodgkin lymphoma reported similar rates of event-free and overall survival with ABVD and BEACOPP; these authors stressed the importance of considering treatment burden, immediate and late toxicities, and associated costs when selecting a regimen.[61]

Induction chemotherapy schedules

The MOPP regimen is given every 28 days for six or more cycles, as follows:

The ABVD regimen is given every 28 days for six or more cycles, as follows:

The A+AVD regimen is given every 28 days for six cycles, as follows:

The Stanford V regimen is given as follows[62] :

The escalated BEACOPP regimen is given every 3 weeks for eight cycles, as follows:

Salvage Chemotherapy Regimens

When induction chemotherapy fails, or patients experience relapse, salvage chemotherapy is generally given. Salvage regimens incorporate drugs that are complementary to those that failed during induction therapy. Commonly used salvage regimens include the following:

Salvage chemotherapy schedules

Single-agent therapy is given as follows:

The ICE regimen is given as follows:

The DHAP regimen is given as follows:

Hematopoietic Stem Cell Transplantation

High-dose chemotherapy (HDC) at doses that ablate the bone marrow is feasible with reinfusion of the patient's previously collected hematopoietic stem cells (autologous transplantation) or infusion of stem cells from a donor source (allogeneic transplantation). Patients with refractory or relapsed Hodgkin lymphoma should be promptly referred to centers capable of HDC with hematopoietic stem cell support.

Historically, hematopoietic stem cells have been obtained from bone marrow, but they are now typically obtained by pheresis of peripheral blood lymphocytes. A validated and relatively safe conditioning regimen for autologous transplantation is the BEAM regimen (carmustine [BCNU], etoposide, cytarabine, melphalan).[7] In addition, Gayoso et al reported success with unmanipulated haploidentical related-donor transplant with a busulfan-based reduced conditioning regimen and post-transplant cyclophosphamide as prophylaxis against graft versus host disease.[63]

Myeloablative chemotherapy

High-dose therapy, which requires hematopoietic stem cell support for recovery, is given according to the BEAM regimen. Different schedules for BEAM exist that vary primarily in the dose of etoposide administered. The following is the version used by Schmitz et al in a key randomized, prospective clinical trial[7] :

Following this chemotherapy regimen, autologous hematopoietic stem cells are administered on day 0.

Brentuximab vedotin is indicated as consolidation therapy following autologous hematopoietic stem cell transplantation (HSCT) in patients with classic Hodgkin lymphoma who are at at high risk of relapse or progression. Approval for this indication was based on the AETHERA clinical trial, in which median progression-free survival was 42.9 months in the brentuximab group versus 24.1 months in the placebo group, a statistically significant improvement of 18.8 months (P=0.001).[64]

The regimen is initiated 4-6 weeks after autologous HSCT as 1.8 mg/kg IV (not to exceed 180 mg/dose) infused over 30 minutes three times weekly for up to 16 cycles, or until disease progression or unacceptable toxicity.[24]

Treatment of Early-Stage, Low-Risk Disease

Patients with clinical stages IA or IIA classical Hodgkin lymphoma who do not have unfavorable factors (ie, bulky mediastinal or >10 cm disease, elevated erythrocyte sedimentation rate [ESR] >50 [or ESR >30 with B symptoms], more than three sites of involvement, extranodal disease) are categorized as having early-stage, low-risk disease.[65, 66]

The treatment of these patients requires an individualized approach that provides enough therapy to eradicate the disease and avoid the long-term toxicity of treatment. Despite the existence of guidelines for the treatment, there must be room for individualized treatment, based on weighing of the benefits of therapy versus long-term toxicity.

In general, early-stage favorable Hodgkin lymphoma is treated with combined chemotherapy and radiation; however, there may be a role for chemotherapy alone. Randomized trials have shown that compared with radiation alone, combination chemotherapy followed by radiation is superior in terms of survival.[67]

The most commonly used regimen is ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) for 2-4 cycles followed by involved-site radiation therapy (ISRT) (usually to 30 Gy). This regimen is the default regimen in the United States.

Current National Comprehensive Cancer Network (NCCN) guidelines give two cycles of the ABVD regimen a category 1 rating (ie, the recommendation is based on high-level evidence and uniform NCCN consensus that the intervention is appropriate), but list the Stanford V regimen as an alternative.[4] Direct comparisons of ABVD with the Stanford V regimen in early-stage favorable disease have not been reported to date.

The number of chemotherapy cycles and doses of radiation vary based on patient population. The German Hodgkin Study Group (GHSG) HD10 trial evaluated patients with early-stage favorable disease (defined as no more than two sites of disease, no extranodal extension, no bulky mediastinal disease, and ESR < 50 [or < 30 with B symptoms]) by looking at the following four different combinations[40] :

This study showed no difference in overall survival, freedom from treatment failure, and progression-free survival among the groups, but it did show significantly less toxicity in the lower chemotherapy and radiation arm.[40] The results suggested that ABVD for two cycles followed by IFRT 20 Gy is an acceptable treatment for patients with early-stage disease.

The question as to whether radiation therapy is needed after combination chemotherapy in the treatment of early-stage disease is a matter of debate. When the largest trial to date (NCIC/Eastern Cooperative Oncology Group [ECOG] HD6 trial) examined ABVD alone versus ABVD followed by radiation in patients with early-stage Hodgkin lymphoma, the investigators reported that the chemotherapy alone arm had superior overall survival based on less late toxicity.[68] However, whether these results are applicable to patients treated on modern protocols with ISRT is unknown.

As discussed under Goals of Therapy and Response Assessment, there is increasing use of mid-treatment positron-emission tomography (PET) scans to guide therapy. Current NCCN guidelines recommend the use of interim PET-CT scans to guide therapy when ABVD is chosen as the initial regimen, regardless of the initial stage of disease.[4]

However, although it is clear that such scans have prognostic value, it remains unclear whether altering therapy based on PET scan results improves treatment outcomes in early-stage disease.[69, 70] The current data support the monitoring of patients with history and physical examination prior to administering each cycle or modality of treatment and prior to obtaining laboratory studies and CT scans. Some experts suggest that PET scans should not be used to alter therapy outside of a clinical trial.

Treatment of Early-Stage Disease with Unfavorable Factors

Patients with early-stage disease and unfavorable prognostic factors (eg, more than three sites of disease, bulky mediastinal disease, elevated erythrocyte sedimentation rate [ESR], extranodal extension) are classified as having early-stage unfavorable Hodgkin lymphoma. These individuals are treated differently than early-stage favorable patients. In general, four to six cycles of chemotherapy are given followed by involved-site radiation therapy (ISRT).

The preferred regimen is ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine), although other regimens are acceptable, including Stanford V and dose-escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). It should be noted that these regimens are chosen not because they have been proven to be superior in managing early-stage disease; rather, they are an extrapolation from treatment of advanced disease, in which ABVD has been shown to have superior outcomes.[71]

At least two trials have compared therapy with escalated-BEACOPP versus ABVD in early-stage, unfavorable Hodgkin lymphoma.[59] These trials have shown that there does not appear to be a benefit to the use of dose-escalated BEACOPP relative to four cycles of ABVD. In addition, the toxicity was greater with BEACOPP therapy.[59] The results of these studies suggest that ABVD for four cycles followed by 30 Gy of IFRT is the current standard of care.

Similarly, in another study that examined alternating dose-escalated BEACOPP with ABVD versus ABVD alone with both regimens followed by IFRT, the escalated-BEACOPP regimen failed not only to show a survival advantage to the dose-intense regimen but also showed increased toxicity.[72]

It is a matter of debate as to whether chemotherapy alone can be used in patients with unfavorable disease. As noted, the only trial completed to date, the HD6 trial, did include patients with unfavorable Hodgkin lymphoma.[68] Given the flaws in design, particularly the use of outdated radiation therapy, the conclusions are limited. Regardless, chemotherapy alone may be an option for early-stage unfavorable patients without bulky disease.

Patients with early-stage disease with bulky mediastinal disease are treated differently than those with early-stage unfavorable disease without bulky mediastinal disease. In the United States, these individuals are usually treated with ABVD for 4-6 cycles, followed by ISRT at 36 Gy.[73]

Currently, the National Comprehensive Cancer Network (NCCN) supports the following treatments[4] :

Ongoing trials will determine if irradiation is needed. Currently, radiation is an important part of therapy, and it is mandatory with the Stanford V regimen.

In addition, as with early-stage favorable Hodgkin lymphoma, there is controversy regarding the role of interim positron emission tomography (PET) scanning. As with early-stage favorable disease, the NCCN endorses the use of PET scanning for restaging. How this impacts survival is not known, but mid-treatment PET scanning remains an option. If this imaging modality is performed, biopsy of positive sites is mandatory before changing treatment.

Treatment of Advanced Disease

Patients are considered to have advanced Hodgkin lymphoma if they demonstrate stage III or IV disease. Chemotherapy is the mainstay of therapy, with radiation reserved for initial bulky sites or residual activity on positron emission tomography (PET) scans, but even in these situations, the role of radiation remains an area of debate. When patients present with advanced disease, they are staged as outlined in Staging, and their prognosis is determined by calculation of the International Prognostic System (IPS) (see Prognosis).

The most commonly used regimen, and one endorsed by the National Comprehensive Cancer Network (NCCN), is ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine).[4, 74, 75] The drugs are administered every 14 days, with one cycle consisting of two administrations. This regimen is most commonly given for up to six cycles (12 doses of chemotherapy), although, occasionally, eight cycles are used. It is important to give the doses as planned (maintenance of dose intensity), and it should be noted that afebrile neutropenia is not a reason to withhold therapy.[76]

There is some suggestion in the literature that granulocyte colony-stimulating factor (G-CSF) may increase rates of bleomycin lung injury, but this has not been confirmed.[77] In fact, the largest series in patients with germ-cell tumors did not show an increased risk of bleomycin lung injury with G-CSF use.[78]

ABVD will result in complete remission (CR) in approximately 80% of patients treated, and up to one quarter of patients will have progressive disease-requiring salvage therapy (see below).[53]

An alternative regimen, escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), is recommended by the NCCN for patients with a poor prognosis, as indicated by an International Prognostic Score (IPS) of 4 or higher.[57] Four cycles of escalated BEACOPP are given, with slow responders receiving four additional cycles.[4]

Escalated BEACOPP has CR rates of up to 95% in some trials,[79] but whether this is superior to ABVD therapy in an era with effective salvage is not known.[58, 59] However, adjustments in the delivery of BEACOPP including a reduced number of cycles has proven to be equally effective as the original schedule but with less toxicity.[80] Again, these modifications have not been compared to ABVD.

For patients with an IPS score of less than 3, the NCCN suggests use of the Stanford V regimen.[4] This regimen is used by some clinicians because of its decreased length of treatment and decreased doses of agents. Initial single-institution studies showed impressive results,[81] but subsequent randomized trials have not shown superiority over ABVD.[82]

Although these data suggest that ABVD remain the standard treatment for most patients, the Stanford V regimen may be appropriate for those patients in whom lower doses of bleomycin and doxorubicin are desired, or in those in whom radiation is going to be administered regardless of therapy response. For patients who cannot receive bleomycin, A+AVD is an appropriate option.

A+AVD is the most recently approved regimen for advanced disease and has been shown to improve modified progression-free survival (time to disease progression, death, or evidence of non-complete response after completion of frontline therapy) compared with ABVD.[54] A higher incidence of febrile neutropenia in the brentuximab vedotin arm identified before the trial was complete led to the use of G-CSF as primary prophylaxis in subsequent patients in that arm of the trial. Peripheral neuropathy was also seen more commonly in patients who received brentuximab vedotin, but pulmonary toxicity less commonly.

Beyond chemotherapy, there is even more controversy regarding the role of radiation in advanced Hodgkin lymphoma. The majority of data to date suggest that radiation improves progression-free survival but without improving overall survival.[83, 84] When administered after ABVD or BEACOPP, radiation probably adds little benefit to the majority of patients.[17, 85] One exception may be those patients with bulky mediastinal disease—which is known to be a poor prognostic marker—whose outcomes may be improved with radiation.[86] It must be noted that if the Stanford V regimen is used, then radiation is an integral part of the regimen and must be given.

The role of interim PET-CT scans in the treatment of advanced Hodgkin lymphoma has become more established. A phase III trial showed that if interim PET-CT is negative after two cycles of ABVD, bleomycin can be stopped (ie, de-escalation to AVD) without compromising efficacy.[45] Notably, in the same trial, patients with a positive PET-CT went on to receive BEACOPP, but there was no randomized comparison of BEACOPP versus ABVD in the PET-positive patients. The 2018 NCCN guidelines support this approach,[4]  which avoids the pulmonary toxicity associated with bleomycin.

In general, the following guidelines may be helpful when treating advanced-stage Hodgkin lymphoma:

Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Early-stage NLPHL can be treated with local excision, involved-field radiation therapy (IFRT), or expectant management (close observation).[87] Advanced-stage disease may represent histologic transformation to T-cell-rich B-cell lymphoma (TCR-BCL) or diffuse large cell B-cell lymphoma (DLBCL), both of which should be treated with a typical non-Hodgkin regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone).

Rituximab is a humanized monoclonal antibody that is specific for CD20, a cell-surface antigen expressed by the malignant lymphocytic and histiocytic (L&H) cells in NLPHL. It is a promising agent that has shown activity in NLPHL. On long-term follow-up, the German Hodgkin Lymphoma Study Group observed a 94% overall response rate, with 8 complete remissions, from their population of 15 patients treated with rituximab for relapsed/refractory NLPHL.[88] The use of rituximab in NLPHL, especially in early-stage disease, should ideally be pursued in the context of a clinical trial.

A phase 2 study by Eichenauer et al found that results with rituximab appear inferior when compared with radiotherapy and combined-modality treatment in patients with early-stage NLPHL. However, the authors concluded that investigation of anti-CD20 antibody–based combinations in patients with NLPHL is indicated.[89]

An era-to-era comparison between ABVD treatment and radiotherapy alone found that treating limited-stage NLPHL similar to classical Hodgkin lymphoma may improve outcome compared with the use of radiation alone.[90]

Treatment in HIV-Infected Patients

In patients with advanced Hodgkin lymphoma and HIV infection, the results with standard chemotherapy can be dramatically improved by simultaneous treatment with highly active antiretroviral therapy (HAART). Such therapy generally involves three drugs: two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a protease inhibitor, a non-nucleoside reverse transcriptase inhibitor (non-NRTI), or a viral fusion inhibitor.

Treatment of Refractory or Relapsed Disease

Patients with Hodgkin lymphoma who have never entered complete remission (CR), or whose disease has relapsed after the attainment of CR, have a very poor prognosis when treated with standard chemotherapy and radiation. Therefore, high-dose chemotherapy with autologous stem cell transplantation is recommended for these patients.[91]

In this procedure, salvage chemotherapy is first administered to help reduce the size of the persistent disease and obtain CR, if possible. The number of cycles to be administered depends on how well the disease is responding to therapy. An optimal situation is one in which the disease enters CR with negative positron emission tomography (PET) scan findings, although one study demonstrated that patients may achieve long-term disease-free survival even if their condition has little or no response.[92]

Following one of the cycles of salvage chemotherapy, hematopoietic stem cells are collected from the peripheral blood by leukapheresis and are stored frozen. Following the administration of myeloablative chemotherapy (eg, BEAM), the stored hematopoietic stem cells are thawed and reinfused into the patient to facilitate hematopoietic recovery. High-dose chemotherapy (HDC) with autologous stem cell transplantation can provide better than 50% long-term, progression-free survival for patients with relapses, although specific predicted outcomes vary widely depending on patient-specific risk factors.

Many questions relating to salvage and HDC therapy for patients with Hodgkin lymphoma need to be addressed and are the subject of ongoing clinical trials. These include the following:

In some cases in which HDC fails, allogeneic stem cell transplantation may be a viable option. In this method, myeloablative therapy (chemotherapy and sometimes radiation therapy) is followed by the infusion of hematopoietic stem cells from a genetically matched donor.[93] This offers the potential for an immunologic antitumor effect from T cells provided by the hematopoietic stem cell donor, which may improve the chances for cure of the disease.

Historically, allogeneic stem cell transplantation for Hodgkin lymphoma has been considered too high-risk for most patients, due to high transplant-related mortality. However, new transplant protocols use less toxic conditioning regimens and may be safer and more effective for patients with refractory Hodgkin lymphoma.[94]

Brentuximab vedotin was approved by the US Food and Drug Administration (FDA) in August 2011 for treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplantation or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for a stem cell transplant. This agent is a CD30-directed antibody-drug conjugate consisting of IgG1 antibody cAC10, specific for human CD30, and the microtubule disrupting agent, monomethyl auristatin E (MMAE, or vedotin).[95]

Results from a study of patients with Hodgkin lymphoma in whom autologous stem cell transplantation and a median of four chemotherapy regimens had failed (n = 102) showed that 73% (95% confidence interval [CI], 65-83%) achieved an objective response to brentuximab vedotin therapy, including 32% with complete remission (95% CI, 23-42%) and 40% with partial remission (95% CI, 32-49%). Response duration averaged 6.7 months (range, 1.3-21.9 months).[96]

Current NCCN guidelines recommend brentuximab vedotin as maintenance therapy for 1 year after high-dose therapy with autologous stem cell rescue (HDT/ASCR). In addition, in selected patients, brentuximab vedotin can be used as second-line therapy prior to HDT/ASCR to minimize the use of more intensive chemotherapy.[4]

In May 2016, the FDA approved the monoclonal antibody nivolumab for the treatment of classic Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin. Approval was based on a combination of the phase 2 CheckMate 205 and phase 1 CheckMate 039 trials with an efficacy analysis conducted on data from 95 patients. Treatment with nivolumab showed an objective response rate (ORR) of 65% (CI 95%: 55-75; 62/95), a complete response rate (CRR) of 7% (CI 95%: 3-15; 7/95), and a partial response rate (PRR) of 58% (CI 95%: 47-68; 55/95). Among responders, the median duration of response was 8.7 months (CI 95%: 6.8-NE; range 0.0+, 23.1+).[97, 98]

In March 2017, pembrolizumab, another monoclonal antibody to programmed cell death-1 protein (PD-1) gained accelerated approval from the FDA for cHL. It is indicated in adults and pediatric patients who have refractory cHL or have relapsed after 3 or more prior lines of therapy. Approval was based on data from the KEYNOTE-087 trial (n=210), which demonstrated an ORR with pembrolizumab averaging ~67% (95% CI: 62, 75), a CRR of 22%, and a PRR of 47%. The median follow-up time was 9.4 months. In the 145 patients who responded to treatement, the median duration of response was 11.1 months.[99]

Complications of Therapy

Cardiac disease

Mantle radiotherapy increases the risk the risk of coronary artery disease, chronic pericarditis, pancarditis, valvular heart disease, and defects in the conduction system.[100, 101] Patients with history of mediastinal radiation have a 3-fold increase in their risk of cardiac death.

A study of patients who had previously undergone mediastinal irradiation for Hodgkin lymphoma but who had no clinical evidence of heart disease demonstrated a significant incidence of silent coronary artery obstruction and previous ventricular damage.[102] Based on these results, it is reasonable to initiate functional screening 5 years after radiation therapy in patients with Hodgkin lymphoma.

Pulmonary disease

The ABVD regimen contains bleomycin, a drug associated with dose-related pulmonary toxicity, mainly interstitial pneumonitis, which may lead to fibrosis. The addition of mantle irradiation enhances lung injury. Pulmonary symptoms, such as cough or dyspnea on exertion, are observed in 50% of patients. Declining pulmonary function is observed in approximately one third of patients during ABVD chemotherapy, with or without radiation therapy. This may necessitate dose reductions or even discontinuation of bleomycin.

Although acute toxicity is common, the incidence of severe long-term pulmonary toxicity is low. Fatal pulmonary toxicity has been reported in up to 2-3% of patients treated with the ABVD regimen.

Secondary cancers

Secondary leukemias and solid tumors are significant causes of morbidity and mortality for patients who have received early therapies, including the MOPP regimen and mantle radiation therapy. With modern therapies that emphasize the widespread use of the ABVD and Stanford V regimens and the application of radiation to involved fields only, the incidence of secondary cancers is expected to be much lower.

The most common secondary malignancy following treatment for Hodgkin lymphoma is lung cancer. Both chemotherapy with alkylating agents and irradiation are associated with a 10-fold increased relative risk of lung cancer. Smoking can further increase the risk. In addition, retrospective data have suggested that survival is worse in Hodgkin lymphoma survivors who develop lung cancer compared with matched cohorts with de novo lung cancer.[103]

Myelodysplastic syndromes/acute myelogenous leukemia (MDS/AML) is a particular concern. In the Stanford case series, the projected risk for developing MDS/AML over a follow-up period of 35 years was 2%, and the relative risk compared with matched controls was 38%. The MOPP regimen is associated with an approximately 5% incidence of MDS/AML. With the ABVD regimen the risk is lower, less than 1%.

MDS/AML is usually seen in the first 3-8 years following treatment for Hodgkin lymphoma; subsequently, the risk appears to decline. These findings are consistent with the biology of secondary leukemias following alkylator therapy. MDS/AML usually develops in the context of an MDS with cytogenetic abnormalities in chromosomes 5 and/or 7. Exposure to alkylating agents (eg, the mechlorethamine used in the MOPP regimen) has been implicated.

Exposure to epipodophyllotoxins (etoposide and teniposide) may also result in AML, which generally develops within 3 years and is associated with chromosomal abnormalities at band 11q23.

Breast cancer is 19 times more likely to occur in patients treated with mantle radiation therapy when they are younger than 30 years. If female patients are exposed to chest radiation therapy when they are younger than 15 years, this relative risk increases to 136. MOPP chemotherapy also produces an increased risk for breast cancer when combined with XRT.

Patients in the Stanford case series were also found to have increased risks of developing a variety of other cancers. These include melanoma, non-Hodgkin lymphoma, soft-tissue sarcoma, salivary gland cancers, pancreatic cancers, and thyroid cancers.

A study by Swerdlow et al found that the risk of second malignancy from chemotherapy alone is lower and affects fewer anatomic sites than combined treatment modalities. The authors concluded the risk of second malignancy was slight after 15 years.[104]

Taken in aggregate, these trial results suggest that altering the treatment paradigms of Hodgkin lymphoma to maximize curability while preventing long-term complications should be a focus of ongoing research. Using the least amount of therapy required to cure the disease and minimize complications should be the goal. Early results have suggested that modification of treatment is feasible and have shown some decreased rates of secondary cancers.[105]

Infertility

The degree of infertility varies widely with the regimen used. MOPP chemotherapy causes permanent infertility in at least 80% of males and approximately 50% of females.[104] The escalated BEACOPP regimen results in infertility in nearly 100% of patients treated.[105] The ABVD and Stanford V regimens pose a lower risk of permanent sterility than regimens that contain an alkylating agent (eg, MOPP chemotherapy).[106]

The EORTC Lymphoma Group reported an 82% rate of recovery of fertility in male patients who were treated without alkylating agents.[107] Given the overall excellent prognosis of Hodgkin lymphoma and the early age of onset, it is important to keep fertility preservation in mind when designing treatment plans for these patients. Options include sperm banking for men and various pharmacologic treatments for women including gonadotropin-releasing hormone agonists, ovarian stimulation, and egg preservation.

Infectious complications

Although not commonly performed, patients who have undergone splenectomy are predisposed to bacterial sepsis secondary to encapsulated microorganisms (especially Streptococcus pneumoniae). Empiric antibiotic therapy should be instituted promptly in patients who have undergone splenectomy and present with fever.

Influenza vaccination annually may help to reduce the incidence and/or complications of influenza in patients who have received bleomycin or chest radiation therapy.

Herpes zoster usually appears in previously irradiated dermatomes, but this condition may also occur in patients who have not been irradiated.

Other complications

Lhermitte syndrome (an electric-shock sensation that radiates along the back and legs upon flexion of the neck) can occur in approximately 15% of patients after mantle irradiation. Lhermitte syndrome is not associated with the development of radiation myelitis, and it does not require treatment. This syndrome may last for many months, but it will eventually resolve without long-term sequelae.

Elevation of thyroid stimulating hormone (TSH) occurs in one-third of adult patients after neck/mediastinal radiation therapy.

Survivors of Hodgkin lymphoma have an increased incidence of fatigue, psychiatric distress (anxiety, depression), employment problems, family issues, and sexual functioning problems, as compared to individuals without this disease or relative to survivors of acute leukemia.[108, 109]

Peripheral neuropathy occurred in 29% of patients receiving brentuximab vedotin as part of the A+AVD regimen as opposed to 17% of those who received ABVD.[54] The neuropathy resolved in 43%of the patients and improved in another 23%.

Complications of Immunotherapy

Nivolumab and pembrolizumab are used as salvage therapy in Hodgkin lymphoma and can have numerous autoimmune side effects as a result of immune checkpoint inhibition. This can include pneumonitis, colitis, nephritis, hypothyroidism, hypopituitarism, and adrenalitis. High-dose corticosteroids may be required to treat these side effects. Hypothyroidism requires thyroid hormone replacement and adrenal insuffiency requires physiologic replacement of corticosteroids and mineralocorticoids.

Long-Term Monitoring

Both the National Comprehensive Cancer Network[4] and the European Society for Medical Oncology (ESMO)[5] guidelines provide recommendations for the long-term follow-up of treated patients with Hodgkin lymphoma who are in complete remission.[4, 5] Most relapses occur in the first 3 years after therapy, and Hodgkin lymphoma is the main cause of mortality in the first 10-15 years of follow-up.[110] Follow-up visits are recommended every 2-4 months for the first 1-2 years and every 3-6 months for the next 3-5 years.

Follow-up examinations include the following[110] :

After 5 years, the NCCN recommends the following surveillance schedule[4] :

Use of PET scans for surveillance in patients with complete remission is specifically not encouraged by the NCCN, due to the possibility of false-positive results.

Lung injury may result from mantle irradiation or ABVD chemotherapy. Baseline tests and follow-up evaluation with pulmonary function tests are recommended. The best parameter to follow is the carbon monoxide diffusion capacity.

Prominent goals in the follow-up of survivors of Hodgkin lymphoma include the following[110] :

Future Directions

As discussed earlier, single-agent brentuximab vedotin, nivolumab, and pembrolizumab may be used in the relapsed/refractory setting either post-transplant or in transplant-ineligible patients. Data comparing these regimens are not yet available, but phase 3 trials are ongoing, including a trial comparing brentuximab vedotin versus pembrolizumab and another phase 3 trial comparing brentuximab vedotin plus nivolumab versus nivolumab alone. Brentuximab vedotin plus nivolumab is also being studied in the frontline setting in a phase 2 trial for older patients (NCT02758717).

Efforts are also under way to incorporate these novel agents into earlier lines of therapy with the hopes of improving outcomes and minimizing toxicities. Early phase studies are ongoing to determine how to use them prior to transplant in the second-line setting. These studies currently include various combinations of brentuximab vedotin and chemotherapy[112, 113, 114, 115] or brentuximab vedotin plus immunotherapy (nivolumab),[116] with preliminary data showing high response rates. To date, there are no randomized trials to establish a standard pre-transplant regimen.

In the frontline setting, the combination of nivolumab followed by nivolumab plus AVD is being studied in patients with advanced-stage disease,[117] with promising early results. 

Finally, an emerging area of research is the use of chimeric antigen receptor (CAR) T-cells to treat Hodgkin lymphoma. This will be an ongoing area of investigation.[118]

Guidelines Summary

Guidelines contributor: Priyank P Patel, MD Hematology/Oncology Fellow, Roswell Park Cancer Institute, University at Buffalo

Diagnosis

Updated guidelines on the management of Hodgkin lymphoma have been issued by the National Comprehensive Cancer Network (NCCN)[4] and the European Society for Medical Oncology (ESMO).[5] The NCCN and ESMO guidelines have very similar recommendations for the diagnostic evaluation.[4, 5] Histological evaluation is required for diagnosis according to the World Health Organization (WHO) classification of either nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) or one of four classic Hodgkin lymphoma (CHL) subtypes, as follows:

The presence of Hodgkin and Reed-Sternberg (HRS) cells is disease defining for CHL. Detection of lymphocyte-predominant (LP) cells is required for the diagnosis of NLPHL

Biopsy recommendations are as follows:

Other recommendations for diagnosis are as follows:

Staging

Both the National Comprehensive Cancer Network (NCCN)[4]  and the European Society for Medical Oncology (ESMO)[5] recommend the Cotswold modified Ann Arbor classification for staging Hodgkin lymphoma (HL).[119] See Table 1, below.

Table 1. Cotswold Modification of Ann Arbor Staging System



View Table

See Table

The ESMO guidelines for staging and risk assessment include the following recommendations[5] :

In 2014, the International Conference on Malignant Lymphomas, a multi-disciplinary team of researchers, representing major lymphoma clinical trial groups and cancer centers from North America, Europe, Japan and Australasia, published guidelines for the evaluation, staging, and response assessment. These guidelines were intended to be an update to the 2007 revised guidelines of the International Harmonization Project.[6] The revised recommendations for staging are as follows[120] :

In addition, these guidelines offered consensus on further modifications to the Ann Arbor staging classification. See Table 2, below.[120]

Table 2. International Conference on Malignant Lymphomas Modification of Ann Arbor Staging



View Table

See Table

Risk Stratification

Based on the clinical scenario, staging, and degree of end-organ damage, patients with Hodgkin lymphoma are further categorized into the following three groups:

National Comprehensive Cancer Network (NCCN) guidelines define unfavorable factors for stage I-II as follows[4] :

The European Society for Medical Oncology (ESMO) guidelines recommend the slightly different definitions of risk factors from the European Organization for Research and Treatment of Cancer /Lymphoma Study Association (EORTC/LSA) and the German Hodgkin Study Group (GSHG), as outlined in Table 3, below.[5]

Table 3. Unfavorable Risk Factors for Stages I and II Hodgkin Lymphoma



View Table

See Table

Patients with advanced disease are further risk stratified using the International Prognostic Score (IPS), which includes the following risk factors (for scoring, each factor receives 1 point)[31] :

Based on the IPS score, patients with advanced disease can be categorized as follows[120] :

Treatment for Classical Hodgkin Lymphoma

Recommendations for primary treatment of classical Hodgkin lymphoma (cHL) vary by stage and risk stratification. Chemotherapy is followed by restaging with PET-CT.

Early-stage favorable disease

Combined modality is the treatment of choice in patients with early-stage cHL. The National Comprehensive Cancer Network (NCCN) guidelines give the ABVD (doxorubicin [Adriamycin]/bleomycin/vinblastine/dacarbazine) regimen a category 1 rating (ie, the recommendation is based on high-level evidence and uniform NCCN consensus that the intervention is appropriate), but also list an 8-week Stanford V regimen (doxorubicin, vinblastine, mechlorethamine [or cyclophosphamide], etoposide, vincristine, bleomycin, and prednisone) as an alternative.[4]

ABVD is administered in four cycles. However, two cycles are suggested in highly selected patients with very favorable disease characterized by the following[4] :

The European Society for Medical Oncology (ESMO) guidelines recommend two to three cycles of ABVD followed by involved-site radiation therapy (ISRT). Alternatively, patients may undergo PET-CT scanning after two cycles of ABVD: PET-postive patients then receive two cycles of BEACOPPesc (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone in escalated dose) followed by 30Gy ISRT; PET-negative patients undergo one cycle of BEACOPPesc followed by 20Gy ISRT.[5]  

ESMO notes that whether RT can be omitted in selected patients with complete metabolic response at interim PET is a matter of debate. However, this approach may be offered to individual patients in whom the late risk of RT is thought to outweigh the short-term benefit of improved disease control.[5]

Early-stage unfavorable disease

The NCCN supports the following treatments for stage I-II unfavorable (non-bulky) CHL[4] :

NCCN recommendations for treatment of early-stage unfavorable (bulky) disease are as follows:

The ESMO guidelines recommend four cycles of ABVD with IFRT. In younger patients (≤60 years) a more intensive treatment can be considered, consisting of two cycles of escalated BEACOPP followed by two cycles of ABVD with IFRT.[5]

Advanced-stage disease

The NCCN supports the following treatments for stage III-IV, (non-bulky) cHL[4] :

The ESMO guidelines recommend the following[5] :

Refractory or relapsed disease

Both the NCCN and ESMO guidelines recommend high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for refractory or relapsed disease. The selection of second-line chemotherapy is determined by comparison with the agents previously used.[4, 5] Brentuximab vedotin is recommended for patients who have a failure of autologous stem cell transplantation or failure of at least two prior multi-agent chemotherapy regimens.[4, 5]

Treatment for NLPHL

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct entity with unique clinical features and a different treatment paradigm. The National Comprehensive Cancer Network (NCCN) prefers involved-site radiation therapy (ISRT) over involved-field radiation therapy (IFRT) for treatment of early-stage favorable NLPHL. (Involved-site fields are generally smaller than classic involved fields.) For early-stage unfavorable or advanced-stage NLPHL, an ABVD regimen (doxorubicin [Adriamycin]/bleomycin/vinblastine/dacarbazine) plus ISRT is recommended. CHOP (cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisone) may also be used.[4]

Rituximab may be considered in combination with ABVD or CHOP. For refractory disease, maintenance rituximab may be considered. Individualized treatment is recommended. At relapse, patients biopsy should be performed due to the high rate of conversion to aggressive B-cell lymphoma.[4]

ESMO recommends IFRT for treatment of patients with stage IA NLPHL who have no risk factors. For early-stage unfavorable or advanced stage disease, the treatment recommendation is identical to that for CHL.[5]

Long-Term Monitoring

Both the National Comprehensive Cancer Network (NCCN)[4] and the European Society for Medical Oncology (ESMO)[5] guidelines provide recommendations for the long-term follow-up of treated patients with Hodgkin lymphoma who are in complete remission. The NCCN recommends interim physical exams and blood tests every 3 to 6 months for 1 to 2 years and then every 6 to 12 months for the next 3 years and then annually.[4] ESMO suggests follow-up every 3 months for the first 6 months, and every 6 months until year 4, then annually.[5]

Follow-up examination recommendations are similar for both guidelines, but those from the NCCN are more detailed. NCCN recommendation for follow-up in the first 5 years include the following[4] :

Recommendations for annual monitoring for late complications after 5 years include the following[5] :

 

Medication Summary

Several chemotherapeutic agents in various combinations are used to treat Hodgkin lymphoma. The combinations vary by the stage of disease and by the treating institution. In patients with relapsing or unresponsive disease, hematopoietic stem-cell transplantation significantly prolongs disease-free survival. Various drug combinations have been used with stem-cell rescue.

Although the intended target is the malignant cells of Hodgkin lymphoma, the effects of chemotherapy on normal cells of the body are considerable and account for the adverse effects observed with these agents. Because most patients with Hodgkin lymphoma are long-term survivors, one of the goals of current therapy is to decrease the long-term adverse effects while maintaining excellent cure rates. The use of different therapeutic agents with nonoverlapping toxicities is one way to achieve this goal. Various combinations of the drugs presented below are used to treat Hodgkin lymphoma .

Although adverse effects vary with each drug, some are common to many drugs. These adverse effects include nausea, vomiting, alopecia, bone marrow suppression, and, less commonly, secondary malignancies.

Cancer chemotherapy is based on an understanding of tumor cell growth and of how drugs affect this growth. After cells divide, they enter a period of growth (ie, phase G1), followed by DNA synthesis (ie, phase S). The next phase is a premitotic phase (ie, G2), then finally a mitotic cell division (ie, phase M).

Cell-division rates vary for different tumors. Most common cancers grow slowly compared with normal tissues, and the growth rate may be decreased in large tumors. This difference allows normal cells to recover more quickly than malignant ones after chemotherapy and is the rationale behind current cyclic dosage schedules.

Mechlorethamine (Mustargen)

Clinical Context:  Mechloroethamine is a component of the MOPP (mechlorethamine, vincristine, procarbazine, prednisone) regimen. It exerts cytotoxic effect by inhibiting rapid proliferation of cancer cells.

Class Summary

Antineoplastic agents interfere with cell reproduction. Some agents are specific to phases of the cell cycle, whereas others (eg, alkylating agents, anthracyclines, cisplatin) are not. Cellular apoptosis (ie, programmed cell death) is another potential mechanism of many antineoplastic agents.

Alkylating antineoplastic agents elicit their effects through the formation of covalent bonds with DNA, which disturbs protein synthesis and cellular division. They are able to form bonds with DNA of all cells, especially those which reproduce rapidly. Because of their nonspecific action on cells, toxicities to normal cells are an issue.

Bleomycin (Blenoxane)

Clinical Context:  Classified as an antibiotic, bleomycin induces free radical-mediated breaks in strands of DNA. This agent is part of the ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, dacarbazine) regimen.

Class Summary

Antibiotic antineoplastic agents are produced by microorganisms and inhibit or prevent the proliferation of neoplasms.

Vinblastine (Velban)

Clinical Context:  Vinblastine is a vinca alkaloid that inhibits mitosis because of interactions with tubulin.

Dacarbazine (DTIC-Dome)

Clinical Context:  Dacarbazine is an alkylating agent that inhibits DNA, RNA, and protein synthesis. It inhibits cell replication in all phases of the cell cycle.

Vincristine (Vincasar PFS, Oncovin)

Clinical Context:  Vincristine is a vinca alkaloid with a mechanism of action similar to that of vinblastine. It is presumed to stop the metaphase stage therefore preventing microtubule formation in the mitotic spindle.

Class Summary

The vinca alkaloid agents are naturally occurring or semisynthetic nitrogenous bases that elicit their cytotoxic effects through tubulin-binding properties and disruption of microtubule function, which lead to metaphase arrest.

Etoposide (Toposar)

Clinical Context:  Etoposide is an epipodophyllotoxin that induces DNA strand breaks by disrupting topoisomerase II activity. This causes cell proliferation to arrest in the late S or early G2 portion of the cell cycle.

Procarbazine (Matulane)

Clinical Context:  Procarbazine is an alkylating agent with a mechanism of action similar to that of dacarbazine: inhibition of DNA, RNA, and protein synthesis. It inhibits cell replication in all phases of the cell cycle. It is part of COPP, BEACOPP and MOPP regimens.

Class Summary

Podophyllotoxin derivative antineoplastic agents have cytotoxic effects on cell growth.

Cyclophosphamide (Cytoxan)

Clinical Context:  Cyclophosphamide is an alkylating agent that is chemically related to nitrogen mustards. The mechanism of action of its active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells.

Class Summary

Cyclophosphamide is a synthetic agent similar to nitrogen mustard. This agent requires activation in the liver to form its active intermediaries, which in turn modify and cross-link DNA, thereby inhibiting DNA, RNA, and protein synthesis. Eventually, apoptosis occurs.

Methotrexate (Rheumatrex, Trexall)

Clinical Context:  Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, which is necessary for conversion of folate to biologically active tetrahydrofolate.

Class Summary

Antimetabolite antineoplastic agents interfere with cell functions by competing for its receptors or enzymes involved in the synthesis of DNA. Tissues that have a high rate of cellular metabolism are most sensitive to the effects.

Doxorubicin (Adriamycin)

Clinical Context:  An anthracycline that functions as a DNA intercalator, doxorubicin inhibits topoisomerase II and produces free radicals, which may destroy DNA. The combination of these 2 events can inhibit the growth of neoplastic cells. Doxorubicin is administered intravenously and distributes widely into bodily tissues, including the heart, kidneys, lungs, liver, and spleen. It does not cross the blood-brain barrier and is excreted primarily in bile.

Class Summary

Anthracycline antineoplastic agents elicit their cytotoxic effects through nucleotide base intercalation and cell membrane lipid-binding. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases.

Brentuximab vedotin (Adcetris)

Clinical Context:  Brentuximab is a CD30-directed antibody-drug conjugate (ADC) that consists of chimeric IgG1 antibody cAC10, which is specific for human CD30, bound to the microtubule-disrupting agent monomethyl auristatin E (MMAE, or vedotin). This agent is indicated for treatment of classic Hodgkin lymphoma (cHL) after failure of autologous stem cell transplant (ASCT) or after failure of at least 2 prior multiagent chemotherapy regimens in patients who are not ASCT candidates. It is also indicated as consolidation treatment post-auto-HSCT in patients with high risk for relapse or disease progression. Additionally, brentuximab vedotin is indicated as first-line therapy for previously untreated stage III-IV cHL in combination with chemotherapy.

Class Summary

Antimicrotubular antineoplastics disrupt the microtubular network in cells by promoting stabilization and assembly. In addition, these agents block the disassembly of microtubules, thereby preventing cell division, leading to cell death.

Nivolumab (Opdivo)

Clinical Context:  Monoclonal antibody which inhibits suppression of T-cells by blocking the interaction between programmed cell death-1 protein and its ligands. Nivolumab is indicated for the treatment of classical Hodgkin lymphoma in patients who have relapsed or shown progression after autologous hematopoietic stem cell transplantation (HSCT) and post transplantation brentuximab vedotin.

Pembrolizumab (Keytruda)

Clinical Context:  Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is indicated for adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL) or who have relapsed after 3 or more prior lines of therapy.

Class Summary

Immunotherapy is emerging for use in hematologic malignancies.

PD-1 and related target PD-ligand 1 (PD-L1) are expressed on the surface of activated T cells under normal conditions. PD-L1/PD-1 interaction inhibits immune activation and reduces T-cell cytotoxic activity when bound.

This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation.

Prednisone (Deltasone)

Clinical Context:  Prednisone is a corticosteroid used to treat leukemias and lymphomas because of its lympholytic activity. Prednisone acts as an immunosuppressant by stimulating the synthesis of enzymes needed to decrease the inflammatory response. It also acts as an anti-inflammatory agent by inhibiting the recruitment of leukocytes and monocyte-macrophages into affected areas via inhibition of chemotactic factors and factors that increase capillary permeability.

Prednisone is readily absorbed via the gastrointestinal tract and metabolized in the liver. Inactive metabolites are excreted via the kidneys. Most of the adverse effects of corticosteroids are dose dependent or duration dependent.

Class Summary

Corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.

What is the WHO classification of Hodgkin lymphoma (Hodgkin disease)?What are the signs and symptoms of Hodgkin lymphoma (Hodgkin disease)?Which lab tests are used in the diagnosis of Hodgkin lymphoma (Hodgkin disease)?Which imaging studies are used in in the diagnosis of Hodgkin lymphoma (Hodgkin disease)?What is the role of histology in the diagnosis of Hodgkin lymphoma (Hodgkin disease)?What is the Ann Arbor classification for stages of Hodgkin lymphoma (Hodgkin disease)?What are general treatment principles for Hodgkin lymphoma (Hodgkin disease)?How are the radiation fields used in the treatment of Hodgkin lymphoma (Hodgkin disease) defined?What are the induction chemotherapy regimens used to treat Hodgkin lymphoma (Hodgkin disease)?What are salvage chemotherapy regimens used for Hodgkin lymphoma (Hodgkin disease)?What are the possible toxicities from treatment of Hodgkin lymphoma (Hodgkin disease)?What is Hodgkin lymphoma (Hodgkin disease)?What is required for the diagnosis of Hodgkin lymphoma (Hodgkin disease)?How is Hodgkin lymphoma (Hodgkin disease) treated?What are the five types of Hodgkin lymphoma (Hodgkin disease)?What is the pathogenesis of classical Hodgkin lymphoma (Hodgkin disease)?What are the four types of classical Hodgkin lymphoma (Hodgkin disease)?What is nodular sclerosing Hodgkin lymphoma (NSHL)?What is mixed-cellularity Hodgkin lymphoma (MCHL)?What is lymphocyte depleted Hodgkin lymphoma (LDHL)?What is lymphocyte-rich Hodgkin lymphoma (LRHL)?What is nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)?What is the role of Epstein-Barr virus (EBV) in the etiology of Hodgkin lymphoma (Hodgkin disease)?What is the role of genetics in the etiology of Hodgkin lymphoma (Hodgkin disease)?Which genetic factors may increase the risk of developing nodular sclerosing Hodgkin lymphoma (Hodgkin disease) (NSHL)?What is the incidence of Hodgkin lymphoma (Hodgkin disease) in the US?What is the global incidence of Hodgkin lymphoma (Hodgkin disease)?How does the incidence of Hodgkin lymphoma (Hodgkin disease) vary by sex and race?How does the incidence of Hodgkin lymphoma (Hodgkin disease) vary by age?What is prognosis of Hodgkin lymphoma (Hodgkin disease)?What is the International Prognostic System (IPS) for Hodgkin lymphoma (Hodgkin disease)?What education about Hodgkin lymphoma (Hodgkin disease) should patients receive?What self-exams should be performed by female patients treated for Hodgkin lymphoma (Hodgkin disease)?What education should patients with Hodgkin lymphoma (Hodgkin disease) receive following splenectomy?Which specialist consultations may be helpful for patients who survive Hodgkin lymphoma (Hodgkin disease)?What are the signs and symptoms of Hodgkin lymphoma (Hodgkin disease)?Which physical findings suggest Hodgkin lymphoma (Hodgkin disease)?Which conditions should be considered in the differential diagnoses of Hodgkin lymphoma (Hodgkin disease)?Which factors may lead to a delay in the diagnosis of Hodgkin lymphoma (Hodgkin disease)?How is Hodgkin lymphoma (Hodgkin disease) differentiated from hemophagocytic syndrome?What are the differential diagnoses for Hodgkin Lymphoma?What is the standard approach to the workup of Hodgkin lymphoma (Hodgkin disease)?What is the role of lab testing in the evaluation of Hodgkin lymphoma (Hodgkin disease)?What is the role of imaging studies in the evaluation of Hodgkin lymphoma (Hodgkin disease)?What is the role of CT scanning in the diagnosis of Hodgkin lymphoma (Hodgkin disease)?What is the role of PET scanning in the staging of Hodgkin lymphoma (Hodgkin disease)?How is the diagnosis of Hodgkin lymphoma (Hodgkin disease) confirmed?What is the role of bone marrow biopsy in the evaluation of Hodgkin lymphoma (Hodgkin disease)?What is the role of thoracentesis in the evaluation of Hodgkin lymphoma (Hodgkin disease)?Which tests are performed if CNS symptoms are present in Hodgkin lymphoma (Hodgkin disease)?How is Hodgkin lymphoma (Hodgkin disease) staged?What do A and B designations for Hodgkin lymphoma (Hodgkin disease) denote?How does Hodgkin lymphoma (Hodgkin disease) spread?What are the treatment options for Hodgkin lymphoma (Hodgkin disease)?How does the definition of early-stage favorable Hodgkin lymphoma (Hodgkin disease) differ among guidelines?What are possible short-term toxicities of Hodgkin lymphoma (Hodgkin disease) treatment?What are possible long-term toxicities of Hodgkin lymphoma (Hodgkin disease) treatment?What are goals of Hodgkin lymphoma (Hodgkin disease) treatment?Which specialist consultations are needed for the management of Hodgkin lymphoma (Hodgkin disease)?What is the cure rate of Hodgkin lymphoma (Hodgkin disease)?How are treatment response criteria defined for Hodgkin lymphoma (Hodgkin disease)?What is the primary goal of Hodgkin lymphoma (Hodgkin disease) treatment?How is therapeutic response assessed in Hodgkin lymphoma (Hodgkin disease)?What is the role of radiation therapy in Hodgkin lymphoma (Hodgkin disease)?How are the radiation fields used to treat Hodgkin lymphoma (Hodgkin disease) defined?What is the standard dose of radiation used for treatment of Hodgkin lymphoma (Hodgkin disease)?Which induction chemotherapy regimens are used for treatment of Hodgkin lymphoma (Hodgkin disease)?When is the MOPP regimen indicated for treatment of Hodgkin lymphoma (Hodgkin disease)?How are the ABVD and A+AVD regimens used in the treatment of Hodgkin lymphoma (Hodgkin disease)?What is the Stanford V regimen for treatment of Hodgkin lymphoma (Hodgkin disease)?What is the BEACOPP regimen for treatment of Hodgkin lymphoma (Hodgkin disease)?How is the MOPP regimen administered in Hodgkin lymphoma (Hodgkin disease)?How are the ABVD and A+AVD regimens administered in Hodgkin lymphoma (Hodgkin disease)?How is the Stanford V regimen administered in Hodgkin lymphoma (Hodgkin disease)?How is the BEACOPP regimen administered in Hodgkin lymphoma (Hodgkin disease)?What are the commonly used salvage regimens for Hodgkin lymphoma (Hodgkin disease)?How is the ICE regimen administered in Hodgkin lymphoma (Hodgkin disease)?How is the DHAP regimen administered in Hodgkin lymphoma (Hodgkin disease)?What is the role of hematopoietic stem cell transplantation in the treatment of Hodgkin lymphoma (Hodgkin disease)?What is the BEAM regimen for Hodgkin lymphoma (Hodgkin disease)?What is early-stage, low risk Hodgkin lymphoma (Hodgkin disease)?What are the treatment options for early-stage, low risk Hodgkin lymphoma (Hodgkin disease)?What are NCCN treatment guidelines for early-stage, low risk Hodgkin lymphoma (Hodgkin disease)?What is the role of radiation therapy in the treatment of early-stage, low risk Hodgkin lymphoma (Hodgkin disease)?What is the role of imaging studies in the treatment of early-stage, low risk Hodgkin lymphoma (Hodgkin disease)?What is early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?What treatment regimens are used for early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?What are the treatment options for Hodgkin lymphoma (Hodgkin disease) with bulky mediastinal disease?What are NCCN treatment guidelines for early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?What is the NCCN recommendation for use of PET scanning in the treatment of early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?What is advanced Hodgkin lymphoma (Hodgkin disease)?What are the commonly used chemotherapy regimen for advanced Hodgkin lymphoma (Hodgkin disease)?What is the role of GCSF in the treatment of Hodgkin lymphoma (Hodgkin disease)?How effective is ABVD in treating advanced Hodgkin lymphoma (Hodgkin disease)?What is the role of the BEACOPP regimen in the treatment of advanced Hodgkin lymphoma (Hodgkin disease)?When is the Stanford V regimen used in treatment of advanced Hodgkin lymphoma (Hodgkin disease)?What is the role of radiation for treatment of advanced Hodgkin lymphoma (Hodgkin disease)?What is the role of PET scanning in the treatment of advanced Hodgkin lymphoma (Hodgkin disease)?What are the treatment options for advanced Hodgkin lymphoma (Hodgkin disease) with and without bulky disease?How is early-stage NLPHL treated?What may improve treatment outcome in patients with HIV and advanced Hodgkin lymphoma (Hodgkin disease)?What is the treatment for relapsed Hodgkin lymphoma (Hodgkin disease)?What remains unknown about salvage and HDC therapy for Hodgkin lymphoma (Hodgkin disease)?What is the role of allogeneic stem cell transplantation in the treatment of Hodgkin lymphoma (Hodgkin disease)?What is the role of brentuximab vedotin in the treatment of Hodgkin lymphoma (Hodgkin disease)?What is the role of nivolumab in the treatment of Hodgkin lymphoma (Hodgkin disease)?What is the role of pembrolizumab in the treatment of Hodgkin lymphoma (Hodgkin disease)?What are the risk factors for cardiac complication of Hodgkin lymphoma (Hodgkin disease) therapy?What are the risk factors for pulmonary complications of Hodgkin lymphoma (Hodgkin disease) therapy?Which secondary cancers are possible complications of Hodgkin lymphoma (Hodgkin disease) therapy?What is the prevalence of infertility following treatment for Hodgkin lymphoma (Hodgkin disease)?What are the possible complications of splenectomy for treatment of Hodgkin lymphoma (Hodgkin disease)?What noninfectious complications may occur following successful treatment of Hodgkin lymphoma (Hodgkin disease)?What are the NCCN and ESMO guidelines for long-term follow-up following complete remission of Hodgkin lymphoma?What should follow-up exams for Hodgkin lymphoma (Hodgkin disease) include?After five years, what is the NCCN recommended surveillance schedule for Hodgkin lymphoma (Hodgkin disease)?What is the role of PET scanning following complete remission (CR) of Hodgkin lymphoma (Hodgkin disease)?What monitoring is needed following ABVD treatment of Hodgkin lymphoma (Hodgkin disease)?What are goals for survivor care of Hodgkin lymphoma (Hodgkin disease)?What is required for diagnosis of Hodgkin lymphoma (Hodgkin disease)?What are biopsy recommendations for Hodgkin lymphoma (Hodgkin disease)?Which symptoms may aid in the diagnosis of Hodgkin lymphoma (Hodgkin disease)?Which classification system is used for Hodgkin lymphoma (Hodgkin disease) staging?What are the ESMO guidelines for staging and risk assessment of Hodgkin lymphoma (Hodgkin disease)?What are the International Conference on Malignant Lymphomas guidelines for the staging of Hodgkin lymphoma (Hodgkin disease)?What are the risk groups for Hodgkin lymphoma (Hodgkin disease)?What are the NCCN guidelines for determining unfavorable factors for stage I-II Hodgkin lymphoma (Hodgkin disease)?How is the International Prognostic Score (IPS) for Hodgkin lymphoma (Hodgkin disease) calculated?How is primary treatment of Hodgkin lymphoma (Hodgkin disease) determined?What are NCCN recommendations for treatment of early-stage favorable Hodgkin lymphoma (Hodgkin disease)?What are NCCN recommendations for treatment of early-stage unfavorable Hodgkin lymphoma (Hodgkin disease)?What are NCCN recommendations for the treatment of advanced Hodgkin lymphoma (Hodgkin disease)?What are NCCN recommendations for treatment of refractory or relapsed Hodgkin lymphoma (Hodgkin disease)?What are the NCCN recommendations for treatment of NLPHL?What are NCCN recommendations for long-term monitoring of Hodgkin lymphoma (Hodgkin disease)?What are NCCN initial follow-up exam recommendations following complete remission of Hodgkin lymphoma (Hodgkin disease)?What are the NCCN five-year follow up exam recommendations following complete remission of Hodgkin lymphoma (Hodgkin disease)?Which medications are used in the treatment of Hodgkin lymphoma (Hodgkin disease)?What is the basis for cyclic dosage of chemotherapy for Hodgkin lymphoma (Hodgkin disease)?Which medications in the drug class Corticosteroids are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class PD-1/PD-L1 Inhibitors are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Antimicrotubular are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Anthracyclines are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Immunosuppressants; Antineoplastics, Antimetabolite; DMARDs, Immunomodulators are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Alkylating, DMARDs, Immunomodulators are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Podophyllotoxin Derivatives are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Vinca Alkaloid are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Antibiotic are used in the treatment of Hodgkin Lymphoma?Which medications in the drug class Antineoplastics, Alkylating are used in the treatment of Hodgkin Lymphoma?

Author

Bradley W Lash, MD, Attending Physician, Lehigh Valley Cancer Institute

Disclosure: Nothing to disclose.

Coauthor(s)

Athanassios Argiris, MD, Professor, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine

Disclosure: Nothing to disclose.

Zachary Wolfe, MD, Fellow in Hematology/Oncology, Lehigh Valley Health Network

Disclosure: Nothing to disclose.

Specialty Editors

Mary L Windle, PharmD, Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Disclosure: Nothing to disclose.

Acknowledgements

Scott K Dessain, MD, PhD Associate Professor, Lankenau Institute for Medical Research

Disclosure: Genentech Speaker's bureau.

Virginia Kaklamani, MD, Fellow, Department of Internal Medicine, Division of Hematology-Oncology, Northwestern University Medical School

Disclosure: Nothing to disclose.

Koyamangalath Krishnan, MD, FRCP, FACP Paul Dishner Endowed Chair of Excellence in Medicine, Professor of Medicine and Chief of Hematology-Oncology, James H Quillen College of Medicine at East Tennessee State University

Koyamangalath Krishnan, MD, FRCP, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society of Hematology, and Royal College of Physicians

Disclosure: Nothing to disclose.

James L Spears, MD Consulting Staff, Bux-Mont Hematology Oncology Medical Associates

James L Spears, MD is a member of the following medical societies: American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Christine Wasilewski, MD, MPH, Fellow, Department of Medicine, Division of Hematology-Oncology, Thomas Jefferson University Hospital

Disclosure: Nothing to disclose.

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
  2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19. 127 (20):2375-90. [View Abstract]
  3. Hentrich M, Maretta L, Chow KU, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol. 2006 Jun. 17(6):914-9. [View Abstract]
  4. [Guideline] NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Version 1.2018 — December 20, 2017; Accessed: March 22, 2018.
  5. [Guideline] Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 May 23. 25 Suppl 3:iii70-5. [View Abstract]
  6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10. 25(5):579-86. [View Abstract]
  7. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15. 359(9323):2065-71. [View Abstract]
  8. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004 Jan. 5(1):11-8. [View Abstract]
  9. Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol. 2005 Sep 10. 23(26):6379-86. [View Abstract]
  10. Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med. 1981 Jan 15. 304(3):135-40. [View Abstract]
  11. Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 2007 Mar 1. 67(5):2382-8. [View Abstract]
  12. Staal SP, Ambinder R, Beschorner WE, Hayward GS, Mann R. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease. Am J Clin Pathol. 1989 Jan. 91(1):1-5. [View Abstract]
  13. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med. 2003 Oct 2. 349(14):1324-32. [View Abstract]
  14. Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol. 1991 Dec. 139(6):1259-65. [View Abstract]
  15. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991 Feb 9. 337(8737):320-2. [View Abstract]
  16. Goldin LR, Pfeiffer RM, Gridley G, Gail MH, Li X, Mellemkjaer L, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004 May 1. 100(9):1902-8. [View Abstract]
  17. Harty LC, Lin AY, Goldstein AM, Jaffe ES, Carrington M, Tucker MA, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood. 2002 Jan 15. 99(2):690-3. [View Abstract]
  18. Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995 Feb 16. 332(7):413-8. [View Abstract]
  19. Mueller NE, Grufferman S. Hodgkin lymphoma. Schottenfeld D, Fraumeni JF Jr , eds. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006. 872-97.
  20. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010 Dec. 42(12):1126-30. [View Abstract]
  21. Cozen W, Li D, Best T, Van Den Berg DJ, Gourraud PA, Cortessis VK, et al. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood. 2012 Jan 12. 119(2):469-75. [View Abstract]
  22. National Cancer Institute. SEER stat fact sheets: Hodgkin lymphoma. Available at http://www.seer.cancer.gov/statfacts/html/hodg.html. Accessed: March 17, 2017.
  23. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan. 68 (1):7-30. [View Abstract]
  24. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov 11. 116(19):3724-34. [View Abstract]
  25. Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer. 1971 Sep 15. 8(2):192-201. [View Abstract]
  26. Cancer Research UK. Hodgkin lymphoma - UK incidence statistics. Available at http://www.cancerresearchuk.org/cancer-info/cancerstats/types/hodgkinslymphoma/incidence/#Overall. Accessed: March 17, 2017.
  27. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK, et al. SEER Cancer Statistics Review, 1973-1994. Available at http://seer.cancer.gov/csr/1973_1994/. Accessed: March 22, 2018.
  28. Howlader N, Noone AM, Krapcho M, et al, eds. Bethesda, Md: National Cancer Institute. Bethesda, et al. SEER Cancer Statistics Review, 1975-2008. (Based on November 2010 SEER data submission, posted to the SEER Website, 2011.). Available at http://seer.cancer.gov/csr/1975_2008/. Accessed: September 27, 2012.
  29. Das P, Ng A, Constine LS, Hodgson DC, Mendenhall NP, Morris DE, et al. ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and II. J Am Coll Radiol. 2008 Oct. 5(10):1054-66. [View Abstract]
  30. Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, et al. ACR Appropriateness Criteria(R) on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol. 2011 May. 8(5):302-8. [View Abstract]
  31. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998 Nov 19. 339(21):1506-14. [View Abstract]
  32. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010 Mar 11. 362(10):875-85. [View Abstract]
  33. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol. 2002 Sep. 13(9):1370-7. [View Abstract]
  34. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
  35. Menard F, Besson C, Rince P, et al. Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis. 2008 Aug 15. 47(4):531-4. [View Abstract]
  36. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10. 25(5):571-8. [View Abstract]
  37. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10. 25(5):571-8. [View Abstract]
  38. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood. 2005 Mar 1. 105(5):1875-80. [View Abstract]
  39. Cosset JM, Henry-Amar M, Meerwaldt JH, Carde P, Noordijk EM, Thomas J, et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer. 1992. 28A(11):1847-50. [View Abstract]
  40. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12. 363(7):640-52. [View Abstract]
  41. DeVita VT Jr. A selective history of the therapy of Hodgkin's disease. Br J Haematol. 2003 Sep. 122(5):718-27. [View Abstract]
  42. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005 Sep 10. 23(26):6400-8. [View Abstract]
  43. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol. 2007 Sep 1. 25(25):3902-7. [View Abstract]
  44. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007 Aug 20. 25(24):3746-52. [View Abstract]
  45. Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 Jun 23. 374 (25):2419-29. [View Abstract]
  46. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol. 2006 Nov. 28(11):711-4. [View Abstract]
  47. Wilder RB, Ng A, Constine LS, et al, for the Expert Panel on Radiation Oncology-Hodgkin's Lymphoma. ACR Appropriateness Criteria(R) Hodgkin's lymphoma--stage III and IV [online publication]. Reston, Va: American College of Radiology; 2010.
  48. Koeck J, Abo-Madyan Y, Lohr F, Stieler F, Kriz J, Mueller RP, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012 May 1. 83(1):268-76. [View Abstract]
  49. Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014 Jul 15. 89 (4):854-62. [View Abstract]
  50. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006 Jul 1. 24(19):3128-35. [View Abstract]
  51. Engert A, Schiller P, Josting A, Herrmann R, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma... J Clin Oncol. 2003 Oct 1. 21(19):3601-8. [View Abstract]
  52. Arakelyan N, Jais JP, Delwail V, Briere J, Moles-Moreau MP, Senecal D, et al. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer. 2010 Sep 1. 116(17):4054-62. [View Abstract]
  53. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19. 327(21):1478-84. [View Abstract]
  54. Connors JM, et al; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 Jan 25. 378 (4):331-344. [View Abstract]
  55. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002 Feb 1. 20(3):630-7. [View Abstract]
  56. Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, et al. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10. 33 (17):1936-42. [View Abstract]
  57. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12. 348(24):2386-95. [View Abstract]
  58. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21. 365(3):203-12. [View Abstract]
  59. Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2011 Aug 10. CD007941. [View Abstract]
  60. Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug. 25 (8):1622-8. [View Abstract]
  61. Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, et al. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Apr 25. [View Abstract]
  62. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2010 Mar. 21(3):574-81. [View Abstract]
  63. Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant. 2016 May 9. [View Abstract]
  64. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9. 385 (9980):1853-62. [View Abstract]
  65. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8. 357(19):1916-27. [View Abstract]
  66. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007 Aug 10. 25(23):3495-502. [View Abstract]
  67. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica. 2010 Mar. 95(3):494-500. [View Abstract]
  68. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 2. 366(5):399-408. [View Abstract]
  69. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005 Jul. 16(7):1160-8. [View Abstract]
  70. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006 Jan 1. 107(1):52-9. [View Abstract]
  71. Advani RH, Horning SJ. Treatment of early-stage Hodgkin's disease. Semin Hematol. 1999 Jul. 36(3):270-81. [View Abstract]
  72. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 Mar 20. 30(9):907-13. [View Abstract]
  73. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12. 363(7):653-62. [View Abstract]
  74. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15. 21(4):607-14. [View Abstract]
  75. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20. 23(36):9208-18. [View Abstract]
  76. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007 Feb. 18(2):376-80. [View Abstract]
  77. Wedgwood A, Younes A. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Dec. 8 Suppl 2:S63-6. [View Abstract]
  78. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest. 1997 Mar. 111(3):657-60. [View Abstract]
  79. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009 Feb 10. 27(5):805-11. [View Abstract]
  80. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12. 379(9828):1791-9. [View Abstract]
  81. Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients [abstract 308]. Blood. 2004. 104:92a.
  82. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD vs. Stanford V /- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma... Blood (ASH Annual Meeting Abstracts). 2010. 116(21):185; (E2496) [abstract 415].
  83. Hoppe RT. Hodgkin's disease--the role of radiation therapy in advanced disease. Ann Oncol. 1996. 7 Suppl 4:99-103. [View Abstract]
  84. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. 1998 Mar. 16(3):818-29. [View Abstract]
  85. Aleman BM, Raemaekers JM, Tomisic R, Baaijens MH, Bortolus R, Lybeert ML, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2007 Jan 1. 67(1):19-30. [View Abstract]
  86. Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10. 28(20):3352-9. [View Abstract]
  87. Portlock CS. Nodular lymphocyte predominant Hodgkin's disease. Cancer Treat Res. 2006. 131:353-62. [View Abstract]
  88. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 1. 111(1):109-11. [View Abstract]
  89. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011 Oct 20. 118(16):4363-5. [View Abstract]
  90. Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011 Oct 27. 118(17):4585-90. [View Abstract]
  91. Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005 Aug 15. 106(4):1473-8. [View Abstract]
  92. Gopal AK, Metcalfe TL, Gooley TA, et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer. 2008 Sep 15. 113(6):1344-50. [View Abstract]
  93. Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May. 10(5):527-32. [View Abstract]
  94. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin''s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb. 93(2):257-64. [View Abstract]
  95. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4. 363(19):1812-21. [View Abstract]
  96. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 Jun 20. 30 (18):2183-9. [View Abstract]
  97. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22. 372 (4):311-9. [View Abstract]
  98. Ansell S, et al. Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039). Blood. 2015. 126(23):
  99. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1. 35 (19):2125-2132. [View Abstract]
  100. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007 Mar 1. 109(5):1878-86. [View Abstract]
  101. Wethal T, Lund MB, Edvardsen T, et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer. 2009 Aug 18. 101(4):575-81. [View Abstract]
  102. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007 Jan 1. 25(1):43-9. [View Abstract]
  103. Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer. 2011 Dec 15. 117(24):5538-47. [View Abstract]
  104. Swerdlow AJ, Higgins CD, Smith P, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncol. 2011 Nov 1. 29(31):4096-104. [View Abstract]
  105. Barbaro PM, Johnston K, Dalla-Pozza L, Cohn RJ, Wang YA, Marshall GM, et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol. 2011 Dec. 22(12):2569-74. [View Abstract]
  106. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2005 Oct 20. 23(30):7555-64. [View Abstract]
  107. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008 Oct. 19(10):1795-801. [View Abstract]
  108. Kornblith AB, Herndon JE 2nd, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998 Mar. 9(3):297-306. [View Abstract]
  109. Loge JH, Abrahamsen AF, Ekeberg, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage. 2000 Feb. 19(2):91-9. [View Abstract]
  110. Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, et al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer. 2010 May-Jun. 34(3):211-27. [View Abstract]
  111. Andre M, Bosly A. BEACOPPescalated versus ABVD in advanced Hodgkin's lymphoma. Lancet Oncol. 2013 Aug 12. [View Abstract]
  112. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar. 16 (3):284-92. [View Abstract]
  113. Garcia-Sanz R, Sureda A, Alonso-Alvarez S, Gonzalez AP, Rodriguez A, et al. Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood. 2015.
  114. Cassaday RD, Fromm J, Cowan AJ, Libby EN III, Philip M, et al. Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. Blood. 2016.
  115. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018 Jul 5. 132 (1):40-48. [View Abstract]
  116. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018 Mar 15. 131 (11):1183-1194. [View Abstract]
  117. Ramchandren R, Fanale M, Rueda A, et al. Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. Blood. 2017. 130(Suppl 1):651.
  118. Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clin Cancer Res. 2017 Mar 1. 23 (5):1156-1166. [View Abstract]
  119. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov. 7 (11):1630-6. [View Abstract]
  120. [Guideline] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20. 32 (27):3059-68. [View Abstract]
  121. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol. 2003 Jun 15. 21(12):2320-5. [View Abstract]
  122. Connors JM, et al; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 Jan 25. 378 (4):331-344. [View Abstract]
  123. Canioni D, Deau-Fischer B, Taupin P, et al. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One. 2009 Jul 22. 4(7):e6341. [View Abstract]
  124. Chang ET, Canchola AJ, Cockburn M, et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood. 2011 Aug 11. 118(6):1591-9. [View Abstract]
  125. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20. 28(27):4199-206. [View Abstract]

Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin and eosin, original magnification x200).

Micrograph of Hodgkin lymphoma in a fine-needle aspiration lymph node specimen (field stain). Eosinophils, Reed-Sternberg cells, plasma cells, and histocytes can be seen.

A Reed-Sternberg cell in Hodgkin lymphoma. Reed-Sternberg cells are large, abnormal lymphocytes that may contain more than one nucleus. Image courtesy of National Cancer Institute.

Nodular sclerosing Hodgkin lymphoma of the mediastinum. The diagnosis is strongly suggested by the presence of distinct nodules on the cut surface of this lymph node.

Very high magnification micrograph of nodular lymphoctye predominant Hodgkin lymphoma (NLPHL), with a popcorn-shaped Reed-Sternberg cell (hematoxylin and eosin).

A computed tomography (CT) scan showing bulk disease in a patient with Hodgkin lymphoma.

This computed tomography scan is from a 46-year patient with Hodgkin lymphoma at the level of the neck. Enlarged lymph nodes are visible on the left side of the neck (red-shaded region).

A positron emission tomography (PET) scan obtained with fluorodeoxyglucose (FDG) that shows increased FDG uptake in a mediastinal lymph node.

This image depicts a computed tomography (CT) scan, positron-emission tomography (PET) scan, and maximum intensity projection (MIP) PET scan from a patient with histologically proven Hodgkin lymphoma.

Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin and eosin, original magnification x200).

Micrograph of Hodgkin lymphoma in a fine-needle aspiration lymph node specimen (field stain). Eosinophils, Reed-Sternberg cells, plasma cells, and histocytes can be seen.

Nodular sclerosing Hodgkin lymphoma of the mediastinum. The diagnosis is strongly suggested by the presence of distinct nodules on the cut surface of this lymph node.

A Reed-Sternberg cell in Hodgkin lymphoma. Reed-Sternberg cells are large, abnormal lymphocytes that may contain more than one nucleus. Image courtesy of National Cancer Institute.

Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin and eosin, original magnification x200).

Very high magnification micrograph of nodular lymphoctye predominant Hodgkin lymphoma (NLPHL), with a popcorn-shaped Reed-Sternberg cell (hematoxylin and eosin).

A positron emission tomography (PET) scan obtained with fluorodeoxyglucose (FDG) that shows increased FDG uptake in a mediastinal lymph node.

A computed tomography (CT) scan showing bulk disease in a patient with Hodgkin lymphoma.

This computed tomography scan is from a 46-year patient with Hodgkin lymphoma at the level of the neck. Enlarged lymph nodes are visible on the left side of the neck (red-shaded region).

This image depicts a computed tomography (CT) scan, positron-emission tomography (PET) scan, and maximum intensity projection (MIP) PET scan from a patient with histologically proven Hodgkin lymphoma.

Stage at Diagnosis Stage Distribution, % 5-year Relative Survival, %
Stage I  (only in originating layer of cells)1592.3
Stage II  (confined to primary site)4093.4
Stage III (spread to regional lymph nodes)2183.0
Stage IV (cancer has metastasized)2072.9
Unstaged482.7
Source: National Cancer Institute. SEER stat fact sheets: Hodgkin lymphoma. Available at: http://www.seer.cancer.gov/statfacts/html/hodg.html. Accessed: September 12, 2018
Stage Area of Involvement
ISingle lymph node group
IIMultiple lymph node groups on same side of diaphragm
IIIMultiple lymph node groups on both sides of diaphragm
Stage Area of Involvement Extranodal (E) Status
ISingle node or adjacent group of nodesSingle extranodal lesions without nodal involvement
IIMultiple lymph node groups on same side of diaphragmStage I or II by nodal extent with limited contiguous extranodal involvement
II bulky*Multiple lymph node groups on same side of diaphragm with bulk >10 cmN/A
IIIMultiple lymph node groups on both sides of diaphragm; nodes above the diaphragm with spleen involvementN/A
IVMultiple noncontiguous extranodal sitesN/A
A/BB symptoms: weight loss >10%, fever, drenching night sweatsN/A
*Stage II bulky disease is defined as limited or advanced on the basis of histology and a number of prognostic factors.
Risk Factor GSHG EORTC/LSA
Age                   –≥50 y
Histology                   –MC or LD
ESR or B symptoms>50 mm/hr if A or >30 if B>50 mm/hr if A or > 30 if B
Mediastinal mass*MMR >0.33MMR >0.35
Number of nodal sites>2>3
Extranodal lesionsAny                   –
* Mediastinal mass is measured on chest x-ray by the mediastinal mass ratio (MMR), which is the maximum width of the mass/maximum intrathoracic diameter.ESR = erythrocyte sedimentation rate; LD = lymphocyte depletion; MC = mixed cellularity.